Incannex Healthcare Limited
IXHLRating Trend
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.66| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 25, 2026 | $-0.14 | $0.13 | — | $200.0K |
| May 15, 2026 | $-0.35 | $-0.60 | — | $200.0K |
| Feb 13, 2026 | $-0.60 | $-0.60 | — | $200.0K |
| Nov 14, 2025 | $-0.60 | $-11.70 | — | $200.0K |
| Sep 29, 2025 | $-0.57 | $-0.00 | $200.0K | $200.0K |
| May 15, 2025 | $-7.21 | $-13.81 | — | $100.0K |
| Feb 14, 2025 | $-9.91 | $-13.20 | $109.0K | $100.0K |
| Nov 14, 2024 | $-10.83 | $-0.76 | $74.0K | $155.0K |
News
Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story from DReAMzz preparation into active clinical execution, with first-patient dosing underway and the balance sheet providing runway for at least 12 months of planned operations.
Scilex (NASDAQ: SCLX - Get Free Report) and Incannex Healthcare (NASDAQ: IXHL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Analyst Recommendations This is a breakdown of recent
Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040 Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026 NEW YORK and MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage bi…
First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation